You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection

    SBC: CONSEGNA PHARMA INC            Topic: CBD192008

    Warfighters in far-forward deployed settings are at risk for exposure to weaponized opioids and subsequent opioid intoxication. Naloxone is ordinarily effective as an immediate opioid poisoning antidote. However, synthetically derived opioids such as carfentanil and fentanyl-derivatives have a half-life that exceeds that of naloxone, subjecting victims to a phenomenon known as renarcotization, req ...

    SBIR Phase II 2022 Department of DefenseOffice for Chemical and Biological Defense
  2. Learning-based Threat Classification and Localization Using Infrared Imaging and Ion Mobility Spectrometry

    SBC: KEF ROBOTICS INC            Topic: CBD212001

    Concealed chemical threats represent a significant hazard to field operators. Even brief exposure to chemicals can cause lasting physical, physiological, and mental damage. Field operators require tools and techniques to more quickly, safely, and reliably locate and identify chemical threats. Chemical detectors typically excel at either threat classification or threat localization, but seldom both ...

    SBIR Phase I 2022 Department of DefenseOffice for Chemical and Biological Defense
  3. Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection

    SBC: CONSEGNA PHARMA INC            Topic: CBD192008

    Warfighters in far-forward deployed settings are at risk for exposure to weaponized opioids and subsequent opioid intoxication. Naloxone is ordinarily effective for immediate opioid reversal. However, synthetically derived opioids such as carfentanil and fentanyl-derivatives have a half-life that exceeds naloxone’s, subjecting victims to a phenomenon known as renarcotization, requiring repeated ...

    SBIR Phase I 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. 3D Printing of Flexible Polymers for Respiratory Protection

    SBC: ACTUATED MEDICAL, INC.            Topic: CBD181001

    Department of Defense personnel must wear respiratory protection continuously when deployed in regions with the danger of chemical or biological attack. Manufacturing respirators/masks using conventional molding methods limits the features that can be designed into the protection. Additive manufacturing provides an ideal approach for manufacturing respirators. Additive Manufacturing enables the ab ...

    SBIR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus

    SBC: EVRYS BIO LLC            Topic: CBD18A002

    In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. Microfiber-Based Closures with Hermetic Sealing for Chem Bio Protective Garments

    SBC: NANOGRIPTECH            Topic: CBD13109

    Future engagements (especially with near-peer threats) present the possibility of a wide range of anticipated operational situations involving the presence of chemical threat agents. With this, deployment of Military Working Dogs (MWDs) is likely. This creates a situational awareness that MWDs are potentially at risk from exposure to a wide range of hazardous chemicals. Potential threat agents inc ...

    SBIR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
  7. Medical Countermeasure Development for Viral Induced Encephalitis Using Single DomainAntibodies

    SBC: ABZYME THERAPEUTICS LLC            Topic: CBD161004

    Alphaviruses, infection with which may cause encephalitis and death, are recognized as potential biological warfare agents. There are noapproved medical countermeasures against Alphaviruses. In Phase I, using Abzymes proprietary in vivo Self-Diversifying Camelid SingleDomain Antibody Library (SDALib) platform, broadly reactive single domain camelid VHH antibodies against equine encephalitis viral ...

    SBIR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Open-Path Optical Analyzer for Quantitative Chemical Weapons Detection

    SBC: MESH INC            Topic: CBD171004

    Existing U.S. military chemical point sensors such as the JCAD can only provide qualitative detection/ identification results for CWAs and TICs. MESH is proposing to develop a low cost, active FTIR system with a variable optical path within a short open external distance from the sensor. This system will be capable of multicomponent analysis including chemical identification and quantification. Lo ...

    SBIR Phase I 2017 Department of DefenseOffice for Chemical and Biological Defense
  9. Human monoclonal antibodies as countermeasures for T-2 mycotoxin

    SBC: ABZYME THERAPEUTICS LLC            Topic: CBD152003

    Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical properties, high toxicity and relative ease to produce, mycotoxin T-2 is classified as apotential biological warfare agent. Currently there are no FDA approved medical countermeasures available for T-2 mycot ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  10. Single domain antibodies as medical countermeasures for viral induced encephalitis

    SBC: ABZYME THERAPEUTICS LLC            Topic: CBD161004

    Alphavirus infection, which may cause encephalitis and death, are recognized as potential biological warfare agents. There are no approved medical countermeasures against diseases caused by Alphaviruses. In this project, thermostable single domain antibodies capable of crossing the blood brain barrier (BBB) and neutralizing encephalitic viruses will be developed using Abzymes proprietary in vivo S ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government